WO2024052563A4 - Myeloid-derived growth factor for use in treating cardiogenic shock - Google Patents
Myeloid-derived growth factor for use in treating cardiogenic shock Download PDFInfo
- Publication number
- WO2024052563A4 WO2024052563A4 PCT/EP2023/074803 EP2023074803W WO2024052563A4 WO 2024052563 A4 WO2024052563 A4 WO 2024052563A4 EP 2023074803 W EP2023074803 W EP 2023074803W WO 2024052563 A4 WO2024052563 A4 WO 2024052563A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- variant
- mydgf
- fragment
- amino acid
- Prior art date
Links
- 102100031789 Myeloid-derived growth factor Human genes 0.000 title claims abstract 22
- 101710164766 Myeloid-derived growth factor Proteins 0.000 title claims abstract 22
- 206010007625 cardiogenic shock Diseases 0.000 title claims abstract 13
- 238000000034 method Methods 0.000 claims abstract 11
- 102000039446 nucleic acids Human genes 0.000 claims abstract 10
- 108020004707 nucleic acids Proteins 0.000 claims abstract 10
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
- 239000013598 vector Substances 0.000 claims abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- 230000008827 biological function Effects 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 241000283984 Rodentia Species 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/35—Animals modified by environmental factors, e.g. temperature, O2
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to the protein myeloid-derived growth factor (MYDGF) or nucleic acids encoding said protein for use in treating and/or preventing cardiogenic shock. The present invention also relates to vectors comprising the nucleic acid, host cells expressing the nucleic acid, pharmaceutical compositions comprising said protein, nucleic acid, vector or host cell for use in treating and/or preventing cardiogenic shock, and to methods for treating and/or preventing cardiogenic shock. The present invention further relates to a method of preparing an animal model of cardiogenic shock, and to animals obtained by said method.
Claims
1. Myeloid-derived growth factor (MYDGF) protein comprising SEQ ID NO: 1 or SEQ ID NO: 3, or a fragment or a variant thereof, wherein the protein or the fragment or the variant thereof exhibits the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3, for use in treating and/or preventing cardiogenic shock.
2. The MYDGF for use according to claim 1, wherein the MYDGF comprises:
(i) SEQ ID NO: 1; or
(ii) a fragment or variant of SEQ ID NO: 1 exhibiting the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1.
3. The MYDGF for use according to claim 1, wherein the MYDGF protein consists of SEQ ID NO: 1, of SEQ ID NO: 3, or of a variant of SEQ ID NO: 3 having 99% sequence identity to SEQ ID NO: 3.
4. A nucleic acid encoding MYDGF protein comprising SEQ ID NO: 1 or SEQ ID NO: 3, or a fragment or a variant thereof, wherein the protein or the fragment or the variant thereof exhibits the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3, for use in treating and/or preventing cardiogenic shock.
5. The nucleic acid for use according to claim 4, wherein the nucleic acid encodes an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 1.
6. A vector comprising the nucleic acid of claim 4 or 5, for use in treating and/or preventing cardiogenic shock.
7. A host cell comprising the vector according to claim 6 and expressing the nucleic acid, for use in treating and/or preventing cardiogenic shock.
41
AMENDED SHEET (ARTICLE 19)
8. A pharmaceutical composition comprising the MYDGF protein or a fragment or a variant thereof according to any one of claims 1 to 3, the nucleic acid according to any one of claims 4 or 5, the vector according to claim 6, or the host cell according to claim 7 for use in treating and/or preventing cardiogenic shock.
9. The pharmaceutical composition for use according to claim 8, wherein said pharmaceutical composition is administered through the oral, intravenous, subcutaneous, intramucosal, intraarterial, intramuscular or intracoronary route.
10. The pharmaceutical composition for use of claim 9, wherein the administration is through one or more bolus injection(s) and/or infusion(s).
11. A method of treating and/or preventing cardiogenic shock, comprising administering to a patient in need thereof a therapeutically effective amount of MYDGF protein comprising SEQ ID NO: 1 or SEQ ID NO: 3, or fragment or variant thereof, wherein the protein or the fragment or the variant thereof exhibits the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3.
12. A method of treating and/or preventing cardiogenic shock comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising myeloid-derived growth factor (MYDGF) protein comprising SEQ ID NO: 1 or SEQ ID NO: 3, or a fragment or a variant thereof, wherein the protein or the fragment or the variant thereof exhibits the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3.
13. The method according to claim 11 or 12, wherein the MYDGF comprises:
(i) SEQ ID NO: 1; or
(ii) wherein the fragment or variant is a fragment or variant of SEQ ID NO: 1 and exhibits the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1.
14. The method according to any one of claims 11 to 13, wherein the MYDGF or fragment or variant thereof is administered through one or more bolus injection(s) and/or infusion(s), preferably in a pharmaceutically accepted carrier and/or excipient.
42
AMENDED SHEET (ARTICLE 19)
15. A method for producing a non-human mammalian model of cardiogenic shock, the method comprising:
(i) transiently ligating a coronary artery of the mammal, (ii) establishing reperfusion, and
(iii) ventilating the mammal with a fraction of inhaled oxygen of about 0.18 or less.
16. The method of claim 15, wherein the non-human mammal is a rodent, preferably wherein the non-human mammal is a mouse.
17. The method of claim 15 or 16, wherein the coronary artery is ligated for about 30 minutes to about 90 minutes before reperfusion is established.
18. The method according to any one of claims 15 to 17, wherein the mammal is ventilated with a fraction of inhaled oxygen of about 0.16.
43
AMENDED SHEET (ARTICLE 19)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263374942P | 2022-09-08 | 2022-09-08 | |
| US63/374,942 | 2022-09-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2024052563A1 WO2024052563A1 (en) | 2024-03-14 |
| WO2024052563A4 true WO2024052563A4 (en) | 2024-04-25 |
Family
ID=88092856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2023/074803 WO2024052563A1 (en) | 2022-09-08 | 2023-09-08 | Myeloid-derived growth factor for use in treating cardiogenic shock |
| PCT/EP2023/074804 WO2024052564A1 (en) | 2022-09-08 | 2023-09-08 | Myeloid-derived growth factor for use in treating cardiogenic shock |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2023/074804 WO2024052564A1 (en) | 2022-09-08 | 2023-09-08 | Myeloid-derived growth factor for use in treating cardiogenic shock |
Country Status (1)
| Country | Link |
|---|---|
| WO (2) | WO2024052563A1 (en) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584341D1 (en) | 1984-08-24 | 1991-11-14 | Upjohn Co | RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA. |
| CA2257137A1 (en) | 1996-06-11 | 1997-12-18 | Merck & Co., Inc. | Synthetic hepatitis c genes |
| WO2004069173A2 (en) | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US20080004232A1 (en) | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP2130547A1 (en) | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| CN110922467A (en) | 2013-01-17 | 2020-03-27 | 汉诺威医学院 | Factor 1 protein, factor 2 protein and inhibitors thereof for treating or preventing diseases |
| WO2021148411A1 (en) | 2020-01-21 | 2021-07-29 | Boehringer Ingelheim International Gmbh | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
| EP4121583A1 (en) * | 2020-03-20 | 2023-01-25 | Yale University | Rapid extracellular antibody profiling (reap) for the discovery and use of said antibodies |
| CN114470163A (en) * | 2022-02-08 | 2022-05-13 | 西安交通大学医学院第一附属医院 | Application of recombinant human medullary growth factor in treating renal ischemia reperfusion injury |
-
2023
- 2023-09-08 WO PCT/EP2023/074803 patent/WO2024052563A1/en unknown
- 2023-09-08 WO PCT/EP2023/074804 patent/WO2024052564A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024052564A1 (en) | 2024-03-14 |
| WO2024052563A1 (en) | 2024-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI234583B (en) | Hyperglycosylated analogs of human erythropoietin and pharmaceutical composition thereof, DNA sequences encoding said analogs, and host cells comprising said sequences | |
| US4831120A (en) | Method for recovering a purified animal growth hormone or polypeptide analog thereof from a bacterial cell | |
| US4876242A (en) | Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast | |
| CA1339032C (en) | Forms of colony stimulating factor-1 | |
| JPH05501350A (en) | Production of vascular endothelial growth factor | |
| SK500890A3 (en) | Dna sequence, a polypeptide having hematopoietic biological property, the use thereof, a pharmaceutical composition, method of transfection and cells cultivation, a kit and an antibody | |
| KR19990076789A (en) | Recombinant Fusion Proteins with Growth Hormone and Serum Albumin | |
| CS275613B6 (en) | Process for preparing insulin analogs | |
| JPH04503808A (en) | New insulin compound | |
| US5158935A (en) | Human epidermal growth factor having substitution at position 11 | |
| JPH06133793A (en) | Mullerian inhibitor-like polypeptide and its preparation | |
| US20160000864A1 (en) | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment | |
| JP2013530148A (en) | Recombinant human G-CSF dimer and its use in the treatment of nervous system diseases | |
| MX2022007546A (en) | Modified interferon-alpha-2 having reduced immunogenicity. | |
| US9593151B2 (en) | Use of fusion protein | |
| CN111777667B (en) | Small peptide and application thereof in preparation of immunoregulation medicine | |
| JPS61111693A (en) | An expression vector containing a λP▲L subscript▼ promoter and a restriction site engineered to conveniently replace the ribosome binding site, a plasmid containing this vector, and a plasmid containing this plasmid. Host, and related methods | |
| WO2024052563A4 (en) | Myeloid-derived growth factor for use in treating cardiogenic shock | |
| NZ542442A (en) | Two albumin molecules, covalently joined to one another other than solely by means of cysteine-cysteine disulphide bridges, that has a half-life greater then naturally produced albumin in a patient with nephrotic syndrome | |
| JP4808316B2 (en) | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells | |
| ES2380022T3 (en) | Interleukin-11 fusion proteins | |
| CN110790841A (en) | Protein nucleic acid compound and preparation method and application thereof | |
| CN113018424B (en) | Application of CST1 in preventing and/or treating liver immune disorder diseases | |
| US5637495A (en) | Plasmids for production of human growth hormone or polypeptide analog thereof, hosts containing the plasmids, products manufactured thereby, and related methods | |
| US5670371A (en) | Bacterial expression of superoxide dismutase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23772127 Country of ref document: EP Kind code of ref document: A1 |